Suntinorexton : Wikipedia, the free encyclopedia

Suntinorexton

Chemical compound

Suntinorexton
Identifiers

IUPAC name N-[(2S,3S)-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
CAS Number	2274802-89-8^Y
PubChem CID	137460941
UNII	FF2NQ35DA4
Chemical and physical data
Formula	C₂₃H₂₈F₂N₂O₄S
Molar mass	466.54 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCS(=O)(=O)N[C@H]1CCN([C@H]1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O
InChI InChI=1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1 Key:MQDUVMBBJZLFHF-PMACEKPBSA-N

Suntinorexton (INNTooltip International Nonproprietary Name) is an experimental orexin receptor agonist.^[1] It acts as a selective agonist of the orexin OX₂ receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.^[2]

References

^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 34 (1): 93–269. 2020. Proposed INN: List 123
^ WO application 2019027058, Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K, "Heterocyclic compound and use therof", published 2019-02-07, assigned to Takeda Pharmaceutical Company.